Co-administration of GnRH-agonist and hCG for final oocyte maturation (double trigger) in patients with low number of oocytes retrieved per number of preovulatory follicles-a preliminary report

Journal of Ovarian Research

Raoul Orvieto¹  Ronit Machtinger¹  Alon Kedem¹  Shir Dar²  Eran Zilberberg¹  Jigal Haas¹ 

[1] Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, Israel

关键词: IVF outcome;    Final oocyte maturation;    GnRH-agonist;    hCG;    GnRH-antagonist;    Oocytes retrieval;   

Others  :  1151818
DOI  :  10.1186/1757-2215-7-77

 received in 2014-07-11, accepted in 2014-07-21,  发布年份 2014

【 摘 要 】

Background

Recently, the co-administration of GnRH agonist and hCG for final oocyte maturation- 40 and 34 hours prior to OPU, respectively (double trigger) was suggested as the treatment of genuine empty follicle syndrome. In the present study, we aim to evaluate whether the double trigger improves the number of oocytes retrieved in patients with low (<50%) number of oocytes retrieved per number of preovulatory follicles.

Methods

In this proof of concept cohort historical study, we compared the stimulation characteristics of 8 IVF cycles, which include the double trigger to the patients’ previous IVF attempt, triggered with hCG-only.

Results

Patients who received the double trigger (study group) had a significantly higher number of oocytes retrieved, number of 2PN, number of embryos transferred and significantly higher proportions of the number of oocytes retrieved to the number of follicles >10 mm and >14 mm in diameter on day of hCG administration, with a tendency toward a higher number of TQE, as compared to their previous cycles (hCG-only trigger). Three ongoing clinical pregnancies were recorded in the study group and none in the hCG-only trigger group.

Conclusions

Co-administration of GnRH-agonist and hCG for final oocyte maturation, 40 and 34 hours prior to OPU, respectively (double trigger), is suggested as a valuable new tool in the armamentarium for treating patients with low/poor oocytes yield despite an apparently normal follicular development and E2 levels and in the presence of optimal hCG levels on the day of OPU.

【 授权许可】

   
2014 Haas et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Penzias AS: Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reprod Biomed Online 2004, 9:43-46.
• [2]Ludwig M, Doody KJ, Doody KM: Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 2003, 79:1051-1059.
• [3]Stevenson TL, Lashen H: Empty follicle syndrome: the reality of a controversial syndrome, a systematic review. Fertil Steril 2008, 90:691-698.
• [4]Mesen TB, Yu B, Richter KS, Widra E, Decherney AH, Segars JH: The prevalence of genuine empty follicle syndrome. Fertil Steril 2011, 96:1375-1377.
• [5]Beck-Fruchter R, Weiss A, Lavee M, Geslevich Y, Shalev E: Empty follicle syndrome: successful treatment in a recurrent case and review of the literature. Hum Reprod 2012, 27:1357-1367.
• [6]Coulam CB, Bustillo M, Schulman JD: Empty follicle syndrome. Fertil Steril 1986, 46:1153-1155.
• [7]Levy G, Hill MJ, Ramirez CI, Correa L, Ryan ME, DeCherney AH, Levens ED, Whitcomb BW: The use of follicle flushing during oocyte retrieval in assisted reproductive technologies: a systematic review and meta-analysis. Hum Reprod 2012, 27:2373-2379.
• [8]Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce JC, for the MERIT: FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod 2007, 22:2404-2413.
• [9]Gonen Y, Balakier H, Powell W, Casper RF: Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990, 71:918-922.
• [10]Shapiro BS, Daneshmand ST, Garner FC, Aguirr M, Thomas S: Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008, 90:231-233.
• [11]Orvieto R: Ovarian hyperstimulation syndrome- an optimal solution for an unresolved enigma. J Ovarian Res 2013, 6:77.
• [12]Kol S, Humaidan P: GnRH agonist triggering: recent developments. Reprod Biomed Online 2013, 26:226-230.
• [13]Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM: Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles. Fertil Steril 2013, 100:1296-1302.